{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T17:24:43Z","timestamp":1783358683028,"version":"3.54.6"},"reference-count":67,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Setting the adequate dose for voriconazole is challenging due to its variable pharmacokinetics. We investigated the impact of hypoalbuminemia (&lt;35 g\/liter) on voriconazole pharmacokinetics in adult intensive care unit (ICU) patients treated with voriconazole (20 samples in 13 patients) as well as in plasma samples from ICU patients that had been spiked with voriconazole at concentrations of 1.5 mg\/liter, 2.9 mg\/liter, and 9.0 mg\/liter (66 samples from 22 patients). Plasma albumin concentrations ranged from 13.8 to 38.7 g\/liter. Total voriconazole concentrations in adult ICU patients treated with voriconazole ranged from 0.5 to 8.7 mg\/liter. Unbound and bound voriconazole concentrations were separated using high-throughput equilibrium dialysis followed by liquid chromatography-tandem mass spectrometry (LC-MSMS). Multivariate analysis revealed a positive relationship between voriconazole plasma protein binding and plasma albumin concentrations (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001), indicating higher unbound voriconazole concentrations with decreasing albumin concentrations. The correlation is more pronounced in the presence of elevated bilirubin concentrations (\n            <jats:italic>P<\/jats:italic>\n            = 0.05). We therefore propose to adjust the measured total voriconazole concentrations in patients with abnormal plasma albumin and total serum bilirubin plasma concentrations who show adverse events potentially related to voriconazole via a formula that we developed. Assuming 50% protein binding on average and an upper limit of 5.5 mg\/liter for total voriconazole concentrations, the upper limit for unbound voriconazole concentrations is 2.75 mg\/liter. Alterations in voriconazole unbound concentrations caused by hypoalbuminemia and\/or elevated bilirubin plasma concentrations cannot be countered immediately, due to the adult saturated hepatic metabolism. Consequently, increased unbound voriconazole concentrations can possibly cause adverse events, even when total voriconazole concentrations are within the reference range.\n          <\/jats:p>","DOI":"10.1128\/aac.03641-14","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T12:54:02Z","timestamp":1409748842000},"page":"6782-6789","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":63,"title":["Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients"],"prefix":"10.1128","volume":"58","author":[{"given":"Kim","family":"Vanstraelen","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Wauters","sequence":"additional","affiliation":[{"name":"Clinical Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Vercammen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"de Loor","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Laboratory of Nephrology and Renal Transplantation, University Hospitals Leuven\/KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Clinical Department of Haematology, Acute Leukaemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"Clinical Department of Laboratory Medicine, Department of Microbiology and Immunology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Pharmacological Sciences, Drug Delivery and Disposition, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Spriet","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704828"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01992.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2166-2172.2004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2007.118844"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.019646"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029769"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00626-12"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00791-07"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01994.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210396576"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-005-1325-7"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00531-11"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq184"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/11539220-000000000-00000"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2013.05.005"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00951-13"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200009000-00023"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.421"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70036-2"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1470-9465.2004.00838.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.24064"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-10"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku031"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FPE04007X"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/106002809502907-802","article-title":"Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia","volume":"29","author":"Dager WE","year":"1995","unstructured":"DagerWEInciardiJFHoweTL. 1995. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann. Pharmacother. 29:667\u2013670.","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/106002809703100301","article-title":"Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia","volume":"31","author":"Anderson GD","year":"1997","unstructured":"AndersonGDPakCDoaneKWGriffyKGTemkinNRWilenskyAJWinnHR. 1997. Revised Winter-Tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann. Pharmacother. 31:279\u2013284.","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/11595650-000000000-00000"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.01.008"},{"issue":"4","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/000456328802500417","article-title":"Serum albumin by dye-binding: bromocresol green or bromocresol purple? The case for conservatism","volume":"25","author":"McGinlay JM","year":"1988","unstructured":"McGinlayJMPayneRB. 1988. Serum albumin by dye-binding: bromocresol green or bromocresol purple? The case for conservatism. Ann. Clin. Biochem. 25(Pt 4):417\u2013421.","journal-title":"Ann. Clin. Biochem."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2005.10.030"},{"key":"e_1_3_2_36_2","first-page":"1924","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"Hardman JG","year":"2001","unstructured":"HardmanJGLimbirdLEGoodman GilmanA (ed). 2001. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed., p 1924\u20132023. R.R. Donnelley and Sons, Chicago, IL.","edition":"10"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198307213090305"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.09.016"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.602"},{"key":"e_1_3_2_40_2","first-page":"138","article-title":"Severe phenytoin intoxication in patients with hypoalbuminaemia","volume":"151","author":"Kemper EM","year":"2007","unstructured":"KemperEMvan KanHJSpeelmanPde GansKBeijnenJHSchellensJH. 2007. Severe phenytoin intoxication in patients with hypoalbuminaemia. Ned. Tijdschr. Geneeskd. 151:138\u2013141. (In Dutch.)","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"e_1_3_2_41_2","first-page":"218","article-title":"Acute visual dysfunction following phenytoin-induced toxicity","volume":"103","author":"Thakral A","year":"2003","unstructured":"ThakralAShenoyRDeleuD. 2003. Acute visual dysfunction following phenytoin-induced toxicity. Acta Neurol. Belg. 103:218\u2013220.","journal-title":"Acta Neurol. Belg."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199011000-00004"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1312359"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-12"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-009-0296-3"},{"key":"e_1_3_2_46_2","first-page":"93","article-title":"Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis","volume":"47","author":"Hagiwara E","year":"2009","unstructured":"HagiwaraEShiiharaJMatsushimaAEnomotoTTagawaASekineATsuchiyaNBabaTShinoharaTEndoTSogoYNishihiraRKomatsuSKatoTOguraTTakahashiH. 2009. Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi 47:93\u201397. (In Japanese.)","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-011-0363-6"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0607-8"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2013.05.025"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis437"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.005"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003088-199529030-00005","article-title":"Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19","volume":"29","author":"Bertilsson L","year":"1995","unstructured":"BertilssonL. 1995. Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet. 29:192\u2013209.","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis599"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(82)90012-2"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197803020-00003"},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007691-198010000-00005","article-title":"Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring","volume":"2","author":"Perucca E","year":"1980","unstructured":"PeruccaE. 1980. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther. Drug Monit. 2:331\u2013344.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.11.1391"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1980.192"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000095"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.731"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.2174\/138620710790596745"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1990.tb00073.x"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)82280-X"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/clinchem\/31.1.60","article-title":"Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid","volume":"31","author":"Barr\u00e9 J","year":"1985","unstructured":"Barr\u00e9JChamouardJMHouinGTillementJP. 1985. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin. Chem. 31:60\u201364.","journal-title":"Clin. Chem."},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03448.x"},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM197603042941005","article-title":"Drug therapy. Binding of drugs to serum albumin (second of two parts)","volume":"294","author":"Koch-Weser J","year":"1976","unstructured":"Koch-WeserJSellersEM. 1976. Drug therapy. Binding of drugs to serum albumin (second of two parts). N. Engl. J. Med. 294:526\u2013531.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-197904030-00001"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1978.tb01652.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03641-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03641-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:44:43Z","timestamp":1645483483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03641-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1128\/AAC.03641-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03641-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-06-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}